232 related articles for article (PubMed ID: 18803653)
1. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL.
Formichi P; Parnetti L; Radi E; Cevenini G; Dotti MT; Federico A
Eur J Neurol; 2008 Nov; 15(11):1252-5. PubMed ID: 18803653
[TBL] [Abstract][Full Text] [Related]
2. CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder.
Formichi P; Parnetti L; Radi E; Cevenini G; Dotti MT; Federico A
Int J Alzheimers Dis; 2010 Aug; 2010():. PubMed ID: 20827312
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
4. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
5. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data.
Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L
J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
[TBL] [Abstract][Full Text] [Related]
12. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
Herukka SK; Hallikainen M; Soininen H; Pirttilä T
Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.
Kandimalla RJ; S P; Bk B; Wani WY; Sharma DR; Grover VK; Bhardwaj N; Jain K; Gill KD
Neurosci Lett; 2011 Jan; 487(2):134-8. PubMed ID: 20599474
[TBL] [Abstract][Full Text] [Related]
14. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
15. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
17. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
18. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
19. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
[TBL] [Abstract][Full Text] [Related]
20. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
